GeneSight

What GeneSight does

GeneSight is a pharmacogenomic (PGx) testing brand operated by Myriad Genetics, Inc. (NASDAQ: MYGN) through its subsidiary Assurex Health, Inc. (dba Myriad Neuroscience), headquartered in Mason, Ohio. The company provides genetic testing services that analyze how patients' genetic variations may affect their responses to medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. Its core offering, the GeneSight Psychotropic test, uses a proprietary weighted multi-gene algorithm that evaluates 14 genes (9 pharmacokinetic and 5 pharmacodynamic) to classify over 60 mental health medications into three categories indicating the likelihood of efficacy and risk of side effects. The test must be ordered by a registered healthcare provider, with results delivered via a secure clinician portal (myGeneSight.com) within approximately 3 days of sample receipt.

The company's underlying technology integrates results from published clinical studies, pharmacology references, and FDA labels into a proprietary classification system. Tests are processed in a CLIA- and CAP-accredited laboratory, and the platform has been validated through 7 clinical studies published in peer-reviewed journals, including the PRIME Care study, the largest pharmacogenomic randomized controlled trial ever conducted in mental health, sponsored by the U.S. Department of Veterans Affairs. The GeneSight MTHFR test extends the offering to assess folate metabolism, and the GeneSight at Home collection kit enables remote sample collection.

GeneSight generates revenue by performing laboratory testing services and billing insurance providers (Medicare, Medicaid, and commercial plans) directly. The company has established a self-pay rate of $330, with 98% of patients paying $330 or less out of pocket. Its go-to-market combines enterprise field sales to register and support healthcare providers with patient-facing demand generation through educational content, testimonials, and an annual GeneSight Mental Health Monitor survey. The provider network includes 25,000+ clinicians, and over 3 million people have taken the test cumulatively.

Name

GeneSight

Legal name

Myriad Genetics, Inc.

Website

https://genesight.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

251–500 employees

Short description

GeneSight is a pharmacogenomic testing brand owned by Myriad Genetics that provides genetic analysis to personalize medication selection for patients with depression, anxiety, ADHD, and other psychiatric conditions, serving a network of 25,000+ healthcare providers in the United States.

Ownership category

akta.pro rank

Product category

Pharmacogenomic Testing Services

NAICS

Medical Laboratories (621511)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Pharmacogenomic testing
• Clinical laboratory services
• Mental health diagnostics
• Personalized medicine testing
• Genetic test services

Headquarters

HQ city

Mason

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Laboratory Testing Services: GeneSight generates revenue by performing pharmacogenomic testing services. The company bills insurance (Medicare, Medicaid, commercial) directly for the test. Patients pay out-of-pocket only if insurance doesn't cover or denies coverage, with 98% of patients paying $330 or less. Financial assistance is available for eligible patients.
2. Insurance Billing: The company bills insurance companies directly. Medicare (Part B) and Medicare Advantage typically cover the full cost ($0 patient responsibility). Commercial insurance coverage varies. The company reviews patient insurance benefits before processing to estimate out-of-pocket costs.
3. Self-Pay Option: Uninsured patients or those whose insurance doesn't cover the test can opt for the reduced self-pay rate of $330. Payment plans are available for costs of $100 or more, spread over up to 12 months interest-free.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

GeneSight is a pharmacogenomic testing service that analyzes clinically important genetic variations in patient DNA to help healthcare providers predict how patients with depression, anxiety, ADHD, and other psychiatric conditions may metabolize or respond to mental health medications. The test must be ordered by a registered clinician and is processed at the company's own CLIA and CAP accredited laboratory, with results typically delivered in approximately 3 days.

Product overview

GeneSight is a pharmacogenomic testing platform offered by Myriad Genetics that provides genetic insights to help personalize mental health medication treatment. The core offering is the GeneSight Psychotropic test, which analyzes how a patient's genes may affect their outcomes with medications for depression, anxiety, ADHD, and other psychiatric conditions. The platform also includes the GeneSight MTHFR test as an add-on to assess folate metabolism. Sample collection is available either in-office via simple cheek swab or through the GeneSight at Home collection kit for remote patients. Results are delivered to clinicians through a secure portal within approximately 3 days of sample receipt.

Differentiator

Problem solved

Functional benefit

Brands

• GeneSight Psychotropic: Pharmacogenomic test analyzing how genetic variations may affect medication outcomes for depression, anxiety, ADHD, and other psychiatric conditions.
• GeneSight MTHFR
• GeneSight at Home
• Myriad Neuroscience

Products and services

• GeneSight Psychotropic

Quantifiable outcome

• Patients who received GeneSight testing saved over $1,000 in total annual medication costs compared to traditional approaches
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Iraq and Afghanistan Veterans of America (IAVA)coreGTM or Marketing Partner · 31 October 2022IAVA partnered with Myriad Genetics to raise awareness about genetic testing and mental health treatment options available to veterans. The partnership included a live event featuring clinical experts sharing new research about treatment for veterans with mental health conditions. IAVA is a leading veterans organization working to connect, represent, and counsel post-9/11 veterans.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is a large national clinical laboratory that offers pharmacogenomic and mental-health-adjacent genetic tests through its broad test menu. It competes with GeneSight at the payer and provider level and shares the CLIA-certified lab model.
• Myriad Genetics: Myriad Genetics is GeneSight's publicly-traded parent company (NASDAQ: MYGN) and a broad incumbent in molecular diagnostics, with overlapping genetic testing infrastructure and other franchises (e.g., oncology, reproductive health) sharing the same lab, billing, and commercial platforms.
• Laboratory Corporation of America (Labcorp): Labcorp is a large national clinical laboratory offering a wide range of PGx and specialty genetic tests, including mental-health-relevant panels. Its scale, payer contracts, and clinician relationships make it an indirect but powerful competitor to GeneSight's specialty PGx franchise.

Direct peers

• PreventionGenetics (part of Exact Sciences): PreventionGenetics is a CLIA-certified clinical DNA testing laboratory offering a broad menu of genetic tests, including pharmacogenomic panels. It competes with GeneSight in the clinical genetic testing market serving healthcare providers and patients.
• Genomind: Genomind is the closest direct competitor to GeneSight in psychiatric pharmacogenomic testing, offering the Genecept Assay and related PGx panels targeting mental-health prescribers with a similar clinician-gated, evidence-led go-to-market model.

Emerging players

• 23andMe: 23andMe is a consumer-facing genetic testing company that has expanded into health-related genetic reports, including pharmacogenomic traits. Its direct-to-consumer model and large customer database make it an adjacent peer for patient-initiated demand dynamics.
• Tempus Labs: Tempus is an emerging precision-medicine player applying AI-driven analytics to molecular and clinical data, including pharmacogenomics. While primarily oncology-focused, its data-platform approach and provider integration overlap with GeneSight's evidence-driven PGx model.
• Color Health: Color Health offers population-scale genetic testing with a CLIA-certified lab and an enterprise/employer distribution model. Its infrastructure and clinical-grade genetic testing overlap with GeneSight, and its employer-driven channel represents a parallel go-to-market approach.
• Castle Biosciences: Castle Biosciences is a molecular diagnostics company that develops and commercializes genomic tests to aid treatment decisions, primarily in oncology and dermatology. It shares GeneSight's evidence-based, clinician-gated, specialty-testing commercial model.
• Coriell Life Sciences: Coriell Life Sciences offers pharmacogenomic interpretation and clinical decision support tools used by health systems and employers. It overlaps with GeneSight in PGx-focused enterprise and health-plan channels, and competes for prescriber mindshare in medication-guided treatment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/GeneSight
• YouTubeyoutube.com/c/genesight
• Facebookfacebook.com/GeneSight
• LinkedInlinkedin.com/showcase/genesight/about
• Instagraminstagram.com/GeneSight

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneSight